Page 1,526«..1020..1,5251,5261,5271,528..1,5401,550..»

Alzheimer’s disease risk linked to a network of genes associated with myeloid cells – Medical Xpress

Posted: June 27, 2017 at 8:41 am

June 26, 2017 PET scan of a human brain with Alzheimer's disease. Credit: public domain

Many genes linked to late-onset Alzheimer's disease (AD) are expressed in myeloid cells and regulated by a single protein, according to research conducted at the Icahn School of Medicine at Mount Sinai and published June 19 in the journal Nature Neuroscience.

Mount Sinai researchers led an international, genome-wide study of more than 40,000 people with and without the disease and found that innate immune cells of the myeloid lineage play an even more central role in Alzheimer's disease pathogenesis than previously thought.

Specifically, the research team identified a network of genes that are implicated in AD and expressed by myeloid cells, innate immune cells that include microglia and macrophages. Furthermore, researchers identified the transcription factor PU.1, a protein that regulates gene expression and, thus, cell identity and function, as a master regulator of this gene network.

"Our findings show that a large proportion of the genetic risk for late-onset AD is explained by genes that are expressed in myeloid cells, and not other cell types," says Alison Goate, DPhil, Professor of Neuroscience and Director of The Ronald M. Loeb Center for Alzheimer's Disease at the Icahn School of Medicine at Mount Sinai and principal author of the study. "Dysregulation of this network is certainly a cause of Alzheimer's, but we have more work to do to better understand this network and regulation by PU.1, to reveal promising therapeutic targets."

Using a combination of genetic approaches to analyze the genomes of 14,406 AD patients, and 25,849 control patients who do not have the disease, researchers found that many genes which are known to influence the age at which AD sets in, are expressed in myeloid cells. This work pinpointed SPI1, a gene that encodes the transcription factor PU.1, as a major regulator of this network of AD risk genes and demonstrated that lower levels of SPI1/PU.1 are associated with later age at onset of AD.

To test the hypothesis that SPI1 expression levels influence expression of other AD risk genes and microglial function, the researchers used a mouse microglial cell line, BV2 cells that can be cultured in a dish. When researchers knocked down expression of SPI1, the gene that produces PU.1 in cells, they found that the cells showed lower phagocytic activity (engulfment of particles), while overexpression of SPI1 led to increased phagocytic activity. Many other AD genes expressed in microglia also showed altered expression in response to this manipulation of SPI1 expression.

"Experimentally altering PU.1 levels correlated with phagocytic activity of mouse microglial cells and the expression of multiple AD genes involved in diverse biological processes of myeloid cells," says Dr. Goate. "SPI1/PU.1 expression may be a master regulator capable of tipping the balance toward a neuroprotective or a neurotoxic microglial function."

The researchers stress that because the PU.1 transcription factor regulates many genes in myeloid cells, the protein itself may not be a good therapeutic target. Instead, further studies of PU.1's role in microglia and AD pathogenesis are necessary, as they may reveal promising downstream targets that may be more effective in modulating AD risk without broad effects on microglial function. Increased understanding is crucial to facilitating the development of novel therapeutic targets for a disease that currently has no cure.

Explore further: Phagocytes in the braingood or bad?

More information: Kuan-lin Huang et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease, Nature Neuroscience (2017). DOI: 10.1038/nn.4587

The role of microglial cells in neurodegenerative disease is not fully understood. But new results from researchers in Munich and Basel suggest that stimulation of this arm of the immune system might well delay the onset ...

Scientists have, for the first time, characterized the molecular markers that make the brain's front lines of immune defensecells called microgliaunique. In the process, they discovered further evidence that microglia ...

Using human skin cells, University of California, Irvine neurobiologists and their colleagues have created a method to generate one of the principle cell types of the brain called microglia, which play a key role in preserving ...

On diagnosis of acute myeloid leukemia, the mesenchymal stem cells (MSCs) in bone marrow often show alterations in gene and protein expression, proliferation capacity, and function, but whether these are a cause or result ...

Glioblastoma is an extremely aggressive brain tumor with limited treatment options. Recent progress in using immunotherapy-based treatment options in other tumor types has spurred interest in developing approaches that might ...

While the definitive causes remain unclear, several genetic and environmental factors increase the likelihood of autism spectrum disorder, or ASD, a group of conditions covering a "spectrum" of symptoms, skills and levels ...

Many cognitive processes, such as decision-making, take place within seconds or minutes. Neuroscientists have longed to capture neuron activity during such tasks, but that dream has remained elusiveuntil now.

Many genes linked to late-onset Alzheimer's disease (AD) are expressed in myeloid cells and regulated by a single protein, according to research conducted at the Icahn School of Medicine at Mount Sinai and published June ...

Neuroscientists from the University of Chicago have developed a computer model that can simulate the response of nerves in the hand to any pattern of touch stimulation on the skin. The tool reconstructs the response of more ...

Viruses have evolved to be highly effective vehicles for delivering genes into cells. Seeking to take advantage of these traits, scientists can reprogram viruses to function as vectors, capable of carrying their genetic cargo ...

Since scientists began studying the brain, they have asked whether the biology they observed can really be tied to external behaviors. Researchers are building a substantial understanding of the biophysical, molecular, and ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Here is the original post:
Alzheimer's disease risk linked to a network of genes associated with myeloid cells - Medical Xpress

Posted in Cell Medicine | Comments Off on Alzheimer’s disease risk linked to a network of genes associated with myeloid cells – Medical Xpress

Cell Therapy Manufacturing Market Report 2017 – Strategies for Pricing, Cost Control, Reimbursement, Distribution … – Business Wire (press release)

Posted: June 27, 2017 at 8:41 am

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "The Market For Cell Therapy Manufacturing - Strategies for Pricing, Cost Control, Reimbursement, Distribution, & More" report to their offering.

This global strategic report provides detailed analysis of ten leading cell therapy companies worldwide, evaluating the strengths of each company, as well as identifying cell therapy products in development, manufacturing strategies, and partnerships.

The report analyzes time frames for cell therapy product development, distribution channels, key trends and technologies impacting cell therapy manufacturing, cost control measures, and challenges and considerations affecting with cell therapy manufacturing.

Additionally, the report identifies cell therapy products that have been reviewed and approved by internationally-recognized regulatory agencies, as well as products brought to market in the U.S. with FDA approval. It also specifies which cell therapies have since been pulled from market, due to factors such as low adoption rates, unsuccessful reimbursement strategies, or high cost of manufacturing.

It provides an overview of the regulatory environment affecting cell therapy manufacturing in key countries worldwide, evaluating the importance of the recent FDA guidelines for Human Cell and Tissue-based Products (HCT/Ps) and the 21st Century Cures Act, as well as accelerated pathways for cell therapy approvals in Japan, including the:

- Act on the Safety of Regenerative Medicine (Law No. 85/2013)

- Pharmaceuticals and Medical Device (PMD) Act (Law No. 84/2013)

Key Topics Covered:

1. Introduction to Cell Therapy Manufacturing

2. Leading Cell Therapy Companies

3. Approved Cell Therapy Products

4. Pricing Analysis for Cell Therapy Products

5. Cost-Control for Cell Therapy Products

6. Time Frames for Cell Therapy Product Development

7. Reimbursement of Cell Therapy Products

8. Distribution Channels for Cell Therapy Products

9. Market Trend Analysis - Key Trends Impacting the Marketplace

10. Technologies Impacting the Cell Therapy Manufacturing Market

11. Market Potential for Autologous vs. Allogeneic Manufacturing

12. Cell Therapy Manufacturing Challenges and Considerations

13. Conclusions

Cell Therapies Mentioned:

- Apligraf (Organogenesis, Inc. & Novartis AG)

- Carticel (Genzyme)

- Cartistem (MEDIPOST)

- ChrondoCelect (TiGenix NV)

- Cupistem (Anterogen)

- Dermagraft (Advanced Tissue Sciences)

- Epicel (Vericel)

- Hearticellgram-AMI (FCB Pharmicell)

- Holoclar (Chiesi Farmaceutici)

- Osteocel (NuVasive)

- Prochymal (Mesoblast)

- Provenge

- Strimvelis (GSK)

- TEMCELL (JCR Pharmaceuticals Co. Ltd., Licensee of Mesoblast Ltd.)

For more information about this report visit https://www.researchandmarkets.com/research/rspfrk/the_market_for

View original post here:
Cell Therapy Manufacturing Market Report 2017 - Strategies for Pricing, Cost Control, Reimbursement, Distribution ... - Business Wire (press release)

Posted in Cell Therapy | Comments Off on Cell Therapy Manufacturing Market Report 2017 – Strategies for Pricing, Cost Control, Reimbursement, Distribution … – Business Wire (press release)

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform – OrthoSpineNews

Posted: June 27, 2017 at 8:41 am

Share this story with your network

Gosselies, Belgium,26 June 2017; 7am CEST BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that the European Patent Office (EPO) has notified the Company of its intention to grant a key patent covering its first-in-class allogeneic cell therapy technology.

Once granted, the patent titled, Osteogenic differentiation of bone marrow stem cells and mesenchymal stem cells using a combination of growth factors, will provide legal protection to Bone Therapeutics both for the manufacturing methods and for the distinct cell type used in its allogeneic cell therapy technology. Specifically, the patent covers methods to manufacture differentiated and biologically active osteoblastic (bone-forming) cells from bone marrow stem cells, using a specific combination of growth factors, and also covers a new class of osteoblastic cells suitable for allogeneic administration to the patient.

Bone Therapeutics will now validate the patent in several countries in the European Union, potentially allowing IP protection for its allogeneic bone cell therapy platform until 2029. Patents from the same patent family have already been granted in Japan, Australia and Singapore and applications are pending in the USA, Canada, India and South Korea. ALLOB, Bone Therapeutics most advanced allogeneic bone cell therapy product, is currently being evaluated in Phase I/IIA clinical trials for delayed-union fractures and spinal fusion, for which interim results are expected in the third quarter this year.

Thomas Lienard, Chief Executive Officer of Bone Therapeutics, commented: This notice from the European Patent Office confirms our allogeneic bone cell therapy technology is both innovative and distinctive. When granted, this European patent will significantly strengthen our IP position in the field of bone cell therapy, giving us further validation for the scientific and commercial development of our cell therapy products whilst also enhancing our position with respect to new partnerships.

Dr. Miguel Forte, Chief Medical Officer of Bone Therapeutics, further noted: Obtaining this patent is an important step in the development of our allogeneic bone cell therapy technology. It will provide a solid IP protection for our current work and for future technological advances, allowing us to continue our efforts to create patient-centric and commercially interesting bone cell therapy solutions.

About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation. Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into osteoblastic, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery. Our primary clinical focus is ALLOB, an allogeneic off-the-shelf cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB, obtained from patients own bone marrow and currently in Phase III development for osteonecrosis and non-union fractures.

Bone Therapeutics cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate coveringnine patent families. Further information is available at: http://www.bonetherapeutics.com.

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in thispress release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Josh Sandberg has been an executive search consultant focused exclusively on orthopedic and spine start-ups since 2004. He has had a tremendous impact in helping his clients avoid costly hiring mistakes by his deep industry knowledge and network. In 2010, Josh co-founded Ortho Spine Companies, which is the parent company of Ortho Spine Distributors (OSD), Surg.io and Ortho Sales Partners (OSP). OSD a searchable database that helps ease the frustration of finding orthopedic distributors throughout the country. Surg.io is the ultimate distributor toolkit that offers distributors the tools necessary to build the foundation of a scalable and highly functioning sales organization. OSP is an end-to-end solution that helps companies approach the Global Market in a cost efficient way. Our team has hundreds of years of experience and can help you navigate the many challenges present in bringing new technologies to the market.

Original post:
Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform - OrthoSpineNews

Posted in Cell Therapy | Comments Off on Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform – OrthoSpineNews

Pleasant Prairie girl heads to Washington to be ‘diabetic superhero’ – Kenosha News

Posted: June 27, 2017 at 8:40 am

PLEASANT PRAIRIE At 6 years old, Addison Morton is headed to Washington, D.C., to tell Congress and the White House not to cut federal funding for Type 1 diabetes research.

The daughter of Brian and Erin Morton, she is the youngest of five Wisconsin children selected to join more than 150 boys and girls ages 4-17 to participate in the Juvenile Diabetes Research Foundations 10th Childrens Congress since 1999.

Addison and her mother will travel to Washington July 24-26 to attend the biennial Childrens Congress. Brian, a pharmacist at St. Catherines Medical Center, likely will join them there, he said Friday.

Like Addison, who had just turned 3 when doctors diagnosed her in November 2013, all the delegates have Type 1 diabetes or, as its often referred to, juvenile diabetes.

Im excited because Ive never been to Washington, D.C., before, and I also want to find a cure, Addison said, between breaks from playing with her brothers, Tucker, 5, and Tate, 4.

What would finding a cure mean to her?

No more diabetes. No more shots. No more pump. No more Dexcom. No more highs and lows, Addison quickly replies.

Draped in Erins lap, Addison cradles her doll Stace, whom she introduces as also having Type 1 diabetes. Stace wears her own mini medical ID bracelet, as well as a tiny pump and continuous glucose monitor replicas.

Unlike people with Type 2 diabetes so-called adult onset diabetes those with Type 1 currently must rely on externally delivered insulin to live.

Most commonly that means injecting the glucose-regulating hormone via hypodermic syringe or increasingly by way of small, portable, electro-mechanical pumps worn on their bodies or attached to their clothing.

Addison rolls up her shirt to reveal an Omnipod by Insulet Corp., affixed with transparent adhesive film to her abdomen, midway between navel and right side. Twisting slightly, she hoists the left side of her shirt just above her waist to show an even smaller device adhered to her back near her hip. Its Insulets Dexcom continuous glucose monitor.

It watches my blood sugar, Addison says.

As with similar CGM systems, Addisons stores and transmits data. Her parents monitor the data using wristwatch-like devices. In addition, Brians cellphone displays it via an app.

Traditional glucose monitors are used at least several times daily for the most accurate information and to calibrate the CGM, but the most recent technology enables Addisons parents to keep an eye on her blood sugar levels day and night. In addition, the data is recorded and retrievable.

Erin recalls how she first suspected a urinary tract infection was causing their daughter to keep soaking through diapers as a 3-year-old until lab tests showed inordinately high amounts of blood sugar in Addisons urine. Subsequent blood tests proved she had Type 1 diabetes.

As a mother, she found herself crying at thoughts that Addison wouldnt be able to enjoy the kinds of things other kids love like ice cream, cookies, playing sports and engaging in other physical activities.

Remember, at that time I had no idea what diabetes is. Weve come a long way from the beginning, Erin said.

She says together she and Brian make a great team supporting their daughter, as well as Tate, who has been identified with four of the five known markers showing he is at high risk for developing Type 1 as a child. They agreed to enroll Tate in an ongoing research study that could lead to forestalling onset of the disease or possibly even leading to a cure.

Meanwhile, Addisons diagnosis apparently has changed their outlooks on life more than her own.

In a handwritten letter to Speaker of the House Paul Ryan applying for selection in JDRFs Childrens Congress, Addison wrote:

Diabetes is all I know. I do the same thing as other kids, but I have a pump and a Dexcom. ... I want to be a diabetic superhero when I grow up and get a cure. That means you can eat whatever you want without insulin. ... I like to talk about (diabetes) and show off my pump and Dexcom. My mom tells me I am already a diabetic superhero. I hope talking about it and showing people will bring awareness and a cure.

Says Erin, Thats what were going to be talking about in Washington: Special Diabetes Research.

They call it SDR, Brian said. The federal government puts $150 million a year into it, and they usually fund it for two years. That accounts for one-third of all federal funding for Type 1 diabetes research. This time, we want to see the spending bill renewed for three years instead of two.

The Childrens Congress focuses on advocacy and entails what Erin anticipates as a steady parade of meetings with congressmen, possibly Administration officials and other influential people in high places. She doesnt expect their schedule to include sightseeing and fun things to do.

Were there for a lot of reasons. Weve got things to do. We dont have a lot of down time, Erin said.

Looking across their backyard, where Addison is leading her younger brothers in exuberantly climbing around an elaborate play set, Erin thinks ahead to their Washington trip.

Shes a really good advocate for diabetes, Erin said, smiling. She has no memory of her life before diabetes. Now, this is all she knows. Shes innocent about it. She doesnt hold anything back. Im so proud of her.

To learn more about the JDRFs 2017 Childrens Congress and to watch Addison Mortons application video, go to http://www.cc.jdrf.org.

View post:
Pleasant Prairie girl heads to Washington to be 'diabetic superhero' - Kenosha News

Posted in Diabetes | Comments Off on Pleasant Prairie girl heads to Washington to be ‘diabetic superhero’ – Kenosha News

Tips for diabetes and prediabetes meal planning – ClickOnDetroit – WDIV Detroit

Posted: June 27, 2017 at 8:40 am

By Mayo Clinic News Network

Poor diet can obviously lead to health problems and weight gain. Conversely, proper food choices help people become healthier and manage certain conditions. For those with diabetes and prediabetes appropriate monitoring and management of diet is extremely important. Mayo Clinic Health System registered dietitian Sue Seykora offers these meal-planning tips to help keep diabetes under control and maybe avoid it all together.

Carbohydrate counting

Carbohydrate counting is a meal-planning approach that focuses on the total number of carbs consumed. It's an easy method to follow and allows variety in food choices that fit preferences and lifestyle.

Most of the foods you eat contain carbs: breads, crackers, pasta, rice, potatoes, milk and many more. Carbs are often thought of as bad foods. In reality, your body needs carbs to create energy. The problem is that many people don't choose healthy types and amounts of carbs. "People should consume healthier carbs like fruits, vegetables, whole grains and low-fat dairy foods. All foods -- even healthy foods -- need portion control," says Seykora.

Although there is no universal amount of carbs you should ingest, the following guidelines serve as a good starting point and can be adjusted as needed (note that one serving of carbs is considered 15 grams):

"Although carb counting is the initial focus for a diabetic diet, protein and fat levels cannot be ignored," says Seykora. "Work with your dietitian to discover how to limit excessive protein and fat in your diet."

The plate method

"Another meal-planning system is the plate method. Not only is this good for people with diabetes and prediabetes, it's a healthy option for anyone," adds Seykora. She shares some basic principles for the plate method:

Actions for people with prediabetes

It's amazing what health-conscious eating and physical activity can do for preventing the progression of diabetes. Try these tactics to improve your health:

Source: http://newsnetwork.mayoclinic.org/discussion/tips-for-prediabetes-and-diabetes-meal-planning

Distributed by LAKANA. This material may not be published, broadcast, rewritten or redistributed.

Originally posted here:
Tips for diabetes and prediabetes meal planning - ClickOnDetroit - WDIV Detroit

Posted in Diabetes | Comments Off on Tips for diabetes and prediabetes meal planning – ClickOnDetroit – WDIV Detroit

New Implants Could Treat Type 2 Diabetes Without Needles – ExtremeTech

Posted: June 27, 2017 at 8:40 am

Implants that deliver a constant metered dose of medication have plenty of promise. Theyre especially useful for making sure patients dont have to orient their daily schedule around their medication times. For the same reasons, theyre a potential solution for patients who tend to forget to take medications that have to be delivered right on schedule. Their major strength is being able to keep a patients serum concentration of their medication at a specific level.

For example: Nexplanon, a hormonal contraceptive implant, delivers a constant dose of medication that keeps a womans progesterone levels within a particular range that prevents her from ovulating. Too high or too low a dose, and everything would get out of whack. But the implant keeps the serum concentration pretty stable.

But because of the steady diffusion of the active substance, such drug-delivery implants arent fabulous for conditions that require medication only when symptoms appear. There hasnt been a lot of luck with an implant for asthma, for example, because we havent surpassed the rescue inhaler for timely asthma treatment. Another condition that has resisted the implant approach is type 2 diabetes. Because type 2 is all about insulin insensitivity, and insulin is something that operates in a tight feedback loop with fluctuating blood glucose levels, you dont necessarily want a blood insulin concentration thats always held stable at the same level.

Not to worry, though: the biotechnologists are on this. Scientists are developing implantable biomedical microelectromechanical systems (bioMEMS) that can monitor your blood chemistry in real time, deliver timed and quantized doses of medication, and phone home to your doctor to report on what theyve done.

Currently people with type 1 diabetes have the option to get an implanted insulin pump that can deliver insulin on demand, so they dont have to stab themselves every time they need insulin. You may have seen these they clip to a persons belt and look a little like a pager. But type 2 diabetes is more related to insulin insensitivity than it is to failure to produce insulin in the first place. Some diabetics can manage their disease through diet alone, and others take metformin by mouth, while more severe cases can become insulin-dependent. Insulin demand changes along with blood sugar and activity levels.

Credit: Intarcia

Successfully managing type 2 diabetes with an implant necessitates real-time monitoring of blood chemistry, and quantized dose delivery. So scientists have been attacking this problem from multiple angles.

Real-time blood chemistry analysis happens via an implanted lab-on-chip (LOC). These tiny but promising devices are around the size of your thumbnail, but their capabilities are huge. From where theyre implanted in well-vascularized connective tissue, they take a continuous account of blood chemistry and perform basic analysis to report what your likely insulin demand will be. Wired UK reports one such LOC capable of monitoring for five separate biomolecules its inductively charged by a battery pack worn outside the skin, and it can report its results via Bluetooth.

As for drug delivery, in November 2016 a company called Intarcia filed for marketing approval with the FDA, in order to market an implantable drug delivery pump (above right) for type 2 diabetes. It would need replacing to top up its proteins once or twice a year. But the rest of the time, it would deliver timely doses of a drug called exatenide that beat another big-name diabetes medication, sitagliptin, in clinical trials.

Now, the biomedical sciences are just as riddled with startups that overpromise and underdeliver as any other industry. But we hate vaporware just as much as you do, which is why were even talking about this thing. Its solid enough that the Bill and Melinda Gates Foundation has invested in the project; theres a version of the implant that can also be used for HIV medications. If they get FDA approval, Intarcia hopes to release the implant in late 2017.

The combined powers of real-time analysis and metered drug delivery present a tantalizing possibility of real relief for type 2 diabetics, especially in difficult cases where blood chemistry just doesnt want to behave. Minding diabetes at home is a laborious and often painful process involving careful time and calorie management, and sometimes needles. But it might not have to be all needles much longer.

Image credit, top: Intarcia

See original here:
New Implants Could Treat Type 2 Diabetes Without Needles - ExtremeTech

Posted in Diabetes | Comments Off on New Implants Could Treat Type 2 Diabetes Without Needles – ExtremeTech

Pet Vet: Diabetes complicates Schnauzer’s surgery – Lewiston Morning Tribune (subscription)

Posted: June 27, 2017 at 8:40 am

Macintosh is a 10-year-old Schnauzer that has diabetes. His caretaker Paula has been treating him with an injection of insulin twice daily for the past 16 months and he has been doing quite well. Paula checks Mac's blood sugar level three to four times weekly and he appears to be well regulated. Recently, Mac has developed a mass along the top of his back just behind his shoulders. When Paula first noticed the mass, it was raised and about the size of pea. It now has grown to about one inch in diameter and has become reddened in color. Paula is understandably concerned about this mass and wants to have it removed but is also very concerned with the increased risk of infection associated with diabetes and surgery.

First of all, I want to congratulate Paula for her good work in treating Mac's diabetes. Diabetes is a common disease in our companions and is a fatal process. It can, however, be very effectively treated with long survival times when the blood sugar is well regulated. I also am thrilled to hear that Paula is able to monitor Mac's blood sugar.

Monitoring blood sugar requires a blood sample that is applied to a special strip which is inserted into a blood sugar or glucose meter. Within a few seconds, the meter responds with a blood sugar number that is ideally kept between 60 and 150 in dogs. Historically, it was very uncommon for caretakers to monitor their companion's blood sugar, but with the advent of newer meters requiring very tiny blood samples, it is now a much easier process.

I won't use the rest of my column to discuss diabetes only because Paula has a valid concern involving Mac's likely need for surgery.

Without question, diabetic patients are at a greater risk of developing infection when compared with patients that do not have the disease. This is because of the microscopic tissue changes that occur with diabetes, as well as the effects the disease has on the immune system. As a result, Mac is at a greater risk of developing an infection with surgery to remove his mass. This however does not mean he can't have the surgery. To put this in what I consider to be proper perspective, let's say there is a one half of one percent chance of a "normal" patient developing an infection with surgery to remove a mass such as Mac's. If a patient with diabetes has a 100 percent increase in the risk for developing infection from a surgery of this type, we are still looking at a mere one percent chance on infection. These are not real numbers, but the point is made.

Mac should have the surgery, and while he's under anesthesia if needed, he should have his teeth cleaned as well. Dental disease can be a source of infection within the body, and as we know, diabetes can increase the chances that this type of infection will spread. I feel with what I know about Mac's case, there is a greater risk for him if the mass is left unaddressed when compared to the chance of infection from the surgery itself. It's also important to have the mass biopsied after removal to know whether or not it will require further follow-up.

Kahler is a veterinarian in Modest, Calif., who writes his column for the Modesto (Calif.) Bee.

Originally posted here:
Pet Vet: Diabetes complicates Schnauzer's surgery - Lewiston Morning Tribune (subscription)

Posted in Diabetes | Comments Off on Pet Vet: Diabetes complicates Schnauzer’s surgery – Lewiston Morning Tribune (subscription)

Self-management program important to your diabetes treatment plan – Journal Advocate

Posted: June 27, 2017 at 8:40 am

Do you struggle to reach blood glucose targets set by your healthcare provider? Taking a group diabetes education program could help, according to a study whose results were released in the Oct. 10, 2011 issue of the Archives of Internal Medicine Journal. The study divided volunteers with uncontrolled diabetes into two groups. One group attended group sessions (5 2-hour sessions held once a week). The other group used a free-form individual program with sessions available a la carte. Over a year's time, those who had attended the group sessions lowered their A1Cs almost twice as much as those using the individual program.

The American Diabetes Association recommends that people enroll in an ADA-approved self-management program. The diabetes self-management program at Sterling Regional MedCenter is an ADA-recognized program, which means the program has met all of the national standards as set forth by the American Diabetes Association to ensure excellence and quality. Taking Charge of Your Diabetes, a five-week program, is scheduled to begin on Monday, July 3, at 1 p.m.

Medicare and other insurance plans may cover all or part of the cost of the program. Ask your physician's office to check on your insurance coverage before referring you into the program. A written referral from your physician is required. Pre-registration is also required. To pre-register or for more information call Glenda Amen, Wellness Manager, at 970-521-3260.

Original post:
Self-management program important to your diabetes treatment plan - Journal Advocate

Posted in Diabetes | Comments Off on Self-management program important to your diabetes treatment plan – Journal Advocate

ASA provides input to USDA, FDA on advances in biotechnology – High Plains Journal

Posted: June 25, 2017 at 11:42 pm

The American Soybean Association submitted comments recently to both the U.S. Department of Agriculture and the U.S. Food and Drug Administration regarding regulations in response to advances in genetic engineering.

ASA included in comments to USDA, that biotechnology is an essential tool in farmers quest to produce enough food to meet the needs of 9.7 billion people by 2050, creating the need for a clear, science-based regulatory system in the U.S. as an example and standard for regulatory systems of biotechnology internationally.

While applauding USDAs efforts to reduce the burden on regulated entities, ASA expressed concern that aspects of the rule as proposed will increase the regulatory burden and stifle research and innovation.

Additionally, ASAs comments to FDA cheered USDAs proposal to exclude certain genome-editing techniques from requiring pre-market approvals because they are low risk and could be found in nature or achieved through traditional breeding methods.

ASA concluded its support saying, Technological advancements such as genome editing offer an additional tool to combat threats while also improving sustainability in production agriculture.

See the original post:
ASA provides input to USDA, FDA on advances in biotechnology - High Plains Journal

Posted in Biotechnology | Comments Off on ASA provides input to USDA, FDA on advances in biotechnology – High Plains Journal

Mum of Corrie McKeague reveals how close police are to finding her son – Cambridge News

Posted: June 25, 2017 at 11:41 pm

The mum of missing airman Corrie McKeague has revealed how close police are to finding her son.

Police have been searching for the 23-year-old at a landfill site in Milton, Cambridgeshire, since March, after he went missing on a night out in Bury St Edmunds on September 24 last year.

Officers believe that the 23-year-old was dumped by a bin lorry into the landfill site.

Nicola Urquhart, 48, believes that Corrie could be found 'literally tomorrow' if he is in the landfill.

On the Find Corrie Facebook page, she wrote: "The police will continue to search this area [the cell] of the landfill until they either find Corrie or the rubbish starts clearly and consistently showing it has gone back too far in date ranges.

"This is why no completion date can be given as this is reviewed daily/weekly."

She added: "Rubbish is still being found with dates and locations to show they are still in the correct area so they are slowly working their way back to the edges of the entire cell.

"Due to the rubbish that is being found, if Corrie is in this landfill he could literally be found tomorrow."

Nicola also wanted to clarify what the 'cell' actually represented, as previously she said that there was a smaller area left to search.

The mother uses the analogy of a football cut in half and filled with rubbish.

"This is what I understand to be the cell, however the reality is if you were to get a medicine ball and cut that in half and place the football inside it, it is actually the edges of the medicine ball that's the edges of the entire cell.

"The police have searched through the rubbish in the football. To empty the football shaped area they were able to say this may take about 10 weeks (which it roughly did).

"And as they got to the edges they could see the dates of the rubbish was going back far too early, prior to when Corrie disappeared.

"On one side however, the rubbish is still being found with dates and locations to show that they are still in the correct area, so they are slowly working their way back to the edges of the entire cell (the edges of the medicine ball).

"So the area they are searching is still the same depth as the middle of the cell as they are no where near the edges yet which means this will take far longer to search than I first understood."

Corrie was last seen on CCTV at 3.24am walking into a refuse area behind a Greggs in Bury St Edmunds.

Police believe the only way that the 23-year-old could have left that area without being spotted by CCTV is through a bin lorry that entered the refuse area to take rubbish from a Biffa bin only hours later.

The airman's mobile was tracked travelling in a similar direction to a bin lorry's route.

The bin lorry's weight was also found to have carried rubbish heavy enough to have contained Corrie's body.

Police and the family are confident that the airman is in the landfill.

Specialists have sifted through more than 5000 tonnes of rubbish so far.

Read the original post:
Mum of Corrie McKeague reveals how close police are to finding her son - Cambridge News

Posted in Cell Medicine | Comments Off on Mum of Corrie McKeague reveals how close police are to finding her son – Cambridge News

Page 1,526«..1020..1,5251,5261,5271,528..1,5401,550..»